Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Weight-loss drugs pilot to begin in UK amid uncertainty over Wegovy launch

Published 07/06/2023, 00:19
Updated 07/06/2023, 16:56
© Reuters. FILE PHOTO: A competitor prepares to go in front of judges at a casting call for the second season of the reality television programme "Dance Your Ass Off", during which overweight or obese contestants hope to lose weight by dancing, in New York December

© Reuters. FILE PHOTO: A competitor prepares to go in front of judges at a casting call for the second season of the reality television programme "Dance Your Ass Off", during which overweight or obese contestants hope to lose weight by dancing, in New York December

By Ludwig Burger and Maggie Fick

(Reuters) - Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk (CSE:NOVOb)'s Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear.

The government's announcement on the 40-million-pound ($50 million) pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the National Health Service's (NHS) specialist weight management scheme.

The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there.

British Prime Minister Rishi Sunak said on Wednesday the pilot and fighting obesity-related diseases could reduce pressure on hospitals.

It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists".

The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

Obesity is one of the leading causes of severe health conditions such as cardiovascular disease, diabetes and cancer, and costs the NHS 6.5 billion pounds a year.

The government said that NICE, short for the National Institute for Health and Care Excellence, was also considering potential use of Eli Lilly (NYSE:LLY)'s Mounjaro, also known as tirzepatide, currently licensed to treat diabetes but expected to win approval to treat obesity as well.

The two-year pilot will be launched after the new weight loss drugs are available in the UK, it said.

DELAYS

Novo's inability to keep up with U.S. demand for Wegovy has effectively delayed the launch in Britain and elsewhere in Europe. It has also had to overcome production problems at a contract manufacturer.

A company spokesperson would not comment on any commitment to supply the programme, but said there had been preliminary discussion on the role of treating obesity as part of the UK government's ambition to bring people back into the workforce.

Eli Lilly said that its Mounjaro drug could be part of the solution, once approved.

The British government said that only 35,000 people would have access to Wegovy under the specialist hospital services, but tens of thousands more could be eligible.

Phil McEwan, CEO of health economics consultancy Heor Ltd in Cardiff, who advises Novo on market access, said the need for specialist services would have been a major bottleneck.

"You have to be referred to specialist care and that’s not the easiest thing to do. The challenge will be to access reimbursement," he said.

Keen interest in the treatment is already showing elsewhere. One of Britain's largest pharmacy chains, Superdrug, said its remote prescriptions service was anticipating significant demand.

"Superdrug Online Doctor has seen five time anticipated levels of registration," a spokesperson told Reuters in April, declining to give numbers.

Outside the U.S., Wegovy has only been launched in Denmark and Norway but major medical insurance schemes there will not pay for it, saying the health benefits would not justify the extra budgeting.

Britain's move is likely to heat up a debate about whether a drug is the right answer to the growing public health problem of obesity or whether there are other ways to encourage healthier lifestyles.

Duane Mellor, a dietitian and senior lecturer at Aston University's medical school, said drugs like Wegovy were a tool, not the solution.

"It’s a political decision to say the government is doing something to tackle health issues linked to obesity ... we need to be much braver and bolder in looking at root causes around access to health care and about making healthy food enjoyable."

Simon Cork, a senior lecturer in physiology at Anglia Ruskin University, said obesity had been shown to be "incredibly difficult" to manage through diet and exercise alone and that Wegovy and similar drugs offered a step change.

"Hence the excitement from the general public and why the UK government seems to be pushing to make the drug available widely," he said.

Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that triggers the feeling of fullness in the body after eating.

© Reuters. FILE PHOTO: A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023.  REUTERS/Jim Vondruska/Illustration

Trials showed it leads to an average weight loss of around 15%, alongside changes to diet and exercise.

($1 = 0.8051 pounds)

Latest comments

Diet and exercise, NOT big pharma
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.